Related Experiment Video
Updated: Jul 4, 2026
Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations
Published on: February 24, 2023
Mechanisms of Therapeutic Resistance and Recent Advances in Glioblastoma Treatment
Emerson Achari1, Farah Ahmady-Nield2,3, Amit Sharma4
1Department of Medicine, Royal Melbourne Hospital, The University of Melbourne, Parkville, Victoria, Australia.
Abstract:
High-grade central nervous system cancers incur a significant burden of care on society. The combination of therapeutic resistance and high mortality makes it both a challenging target and a devastating diagnosis. Of these, one in two is characterized as glioblastoma (GBM) with a median survival rate of only 13.5 months with the current standard of therapy. Modern interventions, such as PD-1 and CTLA-4 checkpoint inhibition and autologous CAR T cell delivery, remain stymied by both the difficult nature of drug delivery to the brain and the inherent immunosuppressive tumor microenvironment. However, recent advances in the characterization of GBM have unveiled promising new therapeutic avenues aiming to target and eliminate the tumor. In this review, we summarize the mechanisms through which GBM is initiated, localized, and eludes therapy responses and provide an update on recent advances made within this therapeutic space to overcome GBM-mediated immunosuppression. We also discuss the challenges with current and next generational treatment strategies before finally exploring the landscape of potential future therapeutic targets.
Insights
Glioblastoma (GBM) is a deadly brain cancer resistant to therapy. New research explores targeting GBM's immunosuppressive environment and delivery challenges to improve patient survival.
Area of Science:
- Neuro-oncology
- Cancer Immunology
- Drug Delivery
Background:
- High-grade central nervous system cancers, particularly glioblastoma (GBM), present significant therapeutic challenges due to resistance and high mortality.
- Current treatments offer limited efficacy, with GBM patients surviving only 13.5 months on average.
- Existing immunotherapies like checkpoint inhibitors and CAR T cells face hurdles in brain drug delivery and the immunosuppressive tumor microenvironment.
Purpose of the Study:
- To review the mechanisms of GBM initiation, progression, and therapeutic evasion.
- To summarize recent advances in overcoming GBM-induced immunosuppression.
- To explore challenges and future therapeutic targets for GBM treatment.
Main Methods:
- Literature review of GBM pathogenesis and therapeutic strategies.
- Analysis of current and emerging treatments, including immunotherapies.
- Discussion of drug delivery and tumor microenvironment challenges.
Main Results:
- GBM employs complex mechanisms to evade immune surveillance and resist therapy.
- Advances are being made in understanding and targeting the GBM immunosuppressive microenvironment.
- Novel therapeutic strategies are emerging to address GBM's unique challenges.
Conclusions:
- Overcoming GBM requires innovative approaches targeting its biology and microenvironment.
- Future therapies may involve combination strategies to enhance drug delivery and immune response.
- Continued research into novel targets is crucial for improving GBM patient outcomes.
Related Concept Videos
02:56Treatment Resistant Cancers
02:56Treatment Resistent Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...